USPTO Examiner MELLER MICHAEL V - Art Unit 1655

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19324396MARINE ORGANISM DERIVED SURFACTANTSeptember 2025February 2026Allow501NoNo
19252680LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOFJune 2025March 2026Allow811NoNo
19206261PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSIONMay 2025February 2026Allow912NoNo
19183742ALBUMIN RICH PEA PROTEIN ISOLATE AND PROCESS FOR PRODUCTION THEREOFApril 2025September 2025Allow501NoNo
18773936OKRA-DERIVED ANTIVIRAL COMPOSITION AND USES THEREOFJuly 2024May 2025Allow1001NoNo
18746153MUNG BEAN HULL EXTRACT WITH ANTIVIRAL EFFECT AND EXTRACTION METHOD THEREOFJune 2024April 2025Allow1001NoNo
18744608PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSIONJune 2024February 2026Allow2001NoNo
18731591BIOCONTROL FORMULATION FOR CONTROLLING PLANT PATHOGENSJune 2024July 2025Allow1421NoNo
18665693Chemical Processes And Apparatuses For Extracting Organic Compounds From Biomass With Volatile Organic Compound RemovalMay 2024August 2024Allow301NoNo
18652734GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USINGMay 2024March 2026Allow2221NoNo
18650432CANNABIDIOL AND ACTIVE DELIVERY SYSTEMSApril 2024March 2025Allow1000NoNo
18597236COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOFMarch 2024December 2024Allow900NoNo
18591599Composition Comprising Elderberry Extract as Effective Component for Preventing, Treating, or Alleviating Andropause SyndromeFebruary 2024April 2025Allow1310NoNo
18591146ANTIMICROBIAL PEPTIDE STIMULATING SANITIZING COMPOSITIONFebruary 2024October 2025Allow1940NoNo
18421784ENCAPSULATED CANNABINOID COMESTIBLE NOBLE METAL COMPOSITIONS AND PRODUCTS, METHODS OF PREPARING SAMEFebruary 2024March 2025Allow1401NoNo
18436343TOPICAL SKIN COMPOSITIONS FOR TREATING ROSACEA AND SKIN REDNESSFebruary 2024December 2024Allow1000NoNo
18433252CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USEFebruary 2024December 2024Allow1002NoNo
18418553INDIVIDUAL DOSING OF CANNABIS AND TOBACCO FOR STANDARDIZATION AND CONTROLJanuary 2024August 2025Abandon1901NoNo
18417543TOPICAL SKIN FORMULATIONSJanuary 2024October 2024Allow900NoNo
18415101Mesenchymal Stem Cell Derived Exosomes And MethodsJanuary 2024June 2025Allow1710NoNo
18401503PROTEIN BASED CANNABIS COMPOSITIONSDecember 2023October 2024Allow1000NoNo
18544077OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAININGDecember 2023May 2025Allow1710NoNo
18537735SYNTHESIS OF A CARBON QUANTUM DOTS AND SILVER NANOPARTICLE COMPOSITIONDecember 2023May 2025Abandon1821NoNo
18529935PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURINGDecember 2023July 2025Allow2010NoNo
18521113COMPOSITIONS FOR SENSITIVE SKINNovember 2023October 2024Allow1100NoNo
18520281COMPOSITION FOR SKIN-WHITENING OR PREVENTING OR IMPROVING SKIN WRINKLES COMPRISING GREEN TEA EXTRACT WHICH HAS MODIFIED AMOUNTS OF INGREDIENTSNovember 2023September 2024Allow1000NoNo
18513032MIXTURE FOR TREATMENT OF RESPIRATORY ILLNESSESNovember 2023December 2024Abandon1311NoNo
18511302A METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTSNovember 2023March 2026Abandon2720NoNo
18388981USES OF CURCUMINOID COMPOSITIONSNovember 2023September 2024Allow1000NoNo
18494658SEAWEED EXTRACTS, ISOLATED COMPOUNDS, AND METHODS OF TREATMENTOctober 2023July 2025Abandon2111NoNo
18382338METHODS FOR PREPARATION OF PLECTRANTHUS AMBOINICUS EXTRACTSOctober 2023May 2025Allow1911NoNo
18490143WATER-BASED CANNABINOID AND OPIOID COMPOSITIONSOctober 2023August 2024Allow1000NoNo
18379585WATER SOLUBLE CANNABIS COMPOSITIONOctober 2023October 2025Abandon2411NoNo
18378020SYSTEM AND METHOD FOR AEROBIC RESPIRATORY TREATMENTOctober 2023December 2025Allow2600NoNo
18483161COMPOSITION AND FUNCTIONAL FOOD FOR PREVENTING MYOPIAOctober 2023January 2026Abandon2821NoNo
18375846Cannabinoid CompositionsOctober 2023August 2024Allow1100NoNo
18368849APPARATUSES, METHODS, AND SYSTEMS FOR EXTRACTION, ISOLATION AND CONVERSION OF VARIOUS CANNABINOIDS, AND MODIFICATIONS OF WHOLE-PLANT HEMP EXTRACTS THEREWITHSeptember 2023March 2025Abandon1810NoNo
18244708METHOD AND COMPOSITION FOR PREVENTING AND TREATING COVID-19 AND LONG COVIDSeptember 2023July 2024Allow1000NoNo
18458727TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLAugust 2023August 2024Allow1100NoNo
18240004ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTSAugust 2023May 2025Allow2101NoNo
18232565DELIVERY OF ACTIVE INGREDIENTS FROM PLANT MATERIALS TO SKINAugust 2023August 2024Allow1200NoNo
18276194PREPARATION METHOD FOR DECELLULARIZED MATRIX BIOMATERIALAugust 2023October 2025Allow2700NoNo
18364692ARTIFICIAL TEARS AND THERAPEUTIC USESAugust 2023February 2025Abandon1901NoNo
18354817COMPOSITIONS FOR PREVENTING AND TREATING VIRAL INFECTIONSJuly 2023February 2026Abandon3111NoNo
18351940Extraction and Purification of CannabinoidsJuly 2023July 2024Allow1200NoNo
18218279EXTRACTING VITAMINS B1 AND C FROM COMMIPHORA MYRRHAJuly 2023November 2025Abandon2821NoYes
18343563COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOFJune 2023December 2023Allow601NoNo
18215797COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTIONJune 2023July 2024Allow1300NoNo
18342018ORAL DISSOLVABLE FILM THAT INCLUDES PLANT EXTRACTJune 2023March 2025Allow2101NoNo
18341980LONG TERM TREATMENT OF HAIR LOSSJune 2023September 2023Allow301NoNo
18213409FORTIFIED CBD OIL FOR TREATMENT OF PTSDJune 2023July 2024Allow1200NoNo
18336575COMPOSITIONS AND METHODS FOR IMMUNE HEALTHJune 2023October 2023Allow401NoNo
18209267METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GELJune 2023February 2025Abandon2010NoNo
18204044Methods for Treating Neurological Disorders Using Nutrient CompositionsMay 2023July 2024Allow1400NoNo
18323860COMPOSITION AND METHOD FOR TREATING AUTISMMay 2023July 2025Abandon2511NoNo
18199797CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOFMay 2023December 2024Allow1901NoNo
18198312Use of Sustainable, Modified and Enhanced Aquaculture Limulus Amebocyte Lysate Protein and Hemolymph Compounds as a Biologic Broad Spectrum Antimicrobial Therapy.May 2023March 2026Abandon3401NoNo
18251869PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FIBROSIS, COMPRISING ISOLATED MITOCHONDRIAMay 2023March 2026Abandon3401NoNo
18301603EMULSIONS AND DERIVATIVES FOR INFUSING HYDROPHOBIC ACTIVE AGENTS INTO AN EDIBLE PRODUCTApril 2023July 2024Allow1500NoNo
18028327TOPICAL COMPOSITIONS CONTAINING MANUKA OIL AND PALMAROSA OIL FOR TREATING SKIN CONDITIONSMarch 2023December 2024Abandon2101NoNo
18188162USE OF CANNABIDIOL IN TREATMENT OF PULMONARY HYPERTENSIONMarch 2023November 2023Allow700NoNo
18124460TREATMENT OF AUTISM WITH CANNABIDIOLMarch 2023October 2024Allow1910NoNo
18122556EXTRACTING VITAMINS B1 AND C FROM COMMIPHORA MYRRHAMarch 2023November 2025Abandon3231NoYes
18118316QUENCHERS THAT SLOW, DECREASE, OR INHIBIT THE FORMATION OF CHEMIEXCITATION-INDUCED CYCLOBUTANE PYRIMIDINE DIMERSMarch 2023February 2025Abandon2321NoNo
18172390BOYSENBERRY, APPLE, AND BLACKCURRANT COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREFORFebruary 2023August 2024Allow1711NoNo
18171983SLEEP DISORDER COMPOSITIONS AND TREATMENTS THEREOFFebruary 2023November 2024Allow2020NoNo
18167765Solvent-Free THCA Extraction ProcessFebruary 2023July 2025Allow2900NoNo
18163115NON-AQUEOUS GEL COMPOSITIONFebruary 2023September 2025Allow3100NoNo
18006765METHOD OF PREVENTING, REDUCING OR DELAYING FATTY LIVER DISEASEJanuary 2023December 2025Abandon3501NoNo
18100758ANTIMICROBIAL COMPOSITIONSJanuary 2023March 2025Abandon2621NoNo
18100763TOPICAL SKIN COMPOSITIONS FOR TREATING ROSACEA AND SKIN REDNESSJanuary 2023November 2023Allow900NoNo
18099943INTRANASAL ADMINSTRATION OF CANNABIGEROL, CBDa, CBGa, & UNCARIA TOMENTOSA HYDROALCOHOLIC EXTRACT COMPOUNDS EMULSIFIED IN SALINE HOMOGENOUS SOLUTION FOR INTRANASAL ADMINISTRATIONJanuary 2023December 2025Allow3501NoNo
18097834TOPICAL SKIN FORMULATIONSJanuary 2023November 2023Allow1000NoNo
18097959NANOEMULSION COMPOSITION OF LAVENDER OIL FOR FOOD PACKAGINGJanuary 2023November 2024Allow2201NoNo
18004945CANNABIS SATIVA EXTRACTS AND THEIR USESJanuary 2023April 2025Allow2711NoNo
18095298DEEP EUTECTIC SOLVENT INCLUDING ONE OR MORE ACTIVE PHARMACEUTICAL INGREDIENTS DERIVED FROM MUSHROOMSJanuary 2023March 2026Abandon3801NoNo
18151117PROCESS FOR MAKING A WATER SOLUBLE, FULL SPECTRUM HEMP OILJanuary 2023October 2025Abandon3301NoNo
18085012COMPOSITIONS FOR SENSITIVE SKINDecember 2022August 2023Allow800NoNo
18067944OIL EXTRACT OF CANNABIS AND METHOD FOR OBTAININGDecember 2022August 2023Allow800NoNo
18061328METHOD OF PRODUCTION OF PHYTOCANNABINOIDS FOR USE IN MEDICAL TREATMENTSDecember 2022August 2024Allow2111NoNo
18072744INDIVIDUAL DOSING OF CANNABIS AND TOBACCO FOR STANDARDIZATION AND CONTROLDecember 2022November 2023Allow1101NoNo
18007660BONE GRAFT SUBSTITUTESDecember 2022December 2025Allow3611NoNo
17926161PLANT COMPOUNDS FOR TREATING ALZHEIMER'S DISEASENovember 2022December 2025Abandon3701NoNo
17990637CANNABIGEROL (CBG) PRODUCTS AND METHODS OF USENovember 2022September 2023Allow2002NoNo
17923721COMPOSITION FOR PROMOTING AND IMPROVING SLEEP AND BEVERAGE CONTAINING SAME, AND MANUFACTURING METHOD THEREOFNovember 2022April 2025Allow3001NoNo
17923749Uses and Formulations of CannabinoidsNovember 2022October 2025Abandon3501NoNo
18052545COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTIONNovember 2022June 2023Allow700NoNo
17977835COMPOSITIONS AND METHODS OF CONTROLLING PESTSOctober 2022December 2025Allow3802NoNo
17921142PHARMACEUTICAL COMPOSITIONS AND USES THEREOF IN TREATING MUSCLE ATROPHYOctober 2022May 2025Allow3101NoNo
18048954PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURINGOctober 2022July 2023Allow900NoNo
17970395TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLOctober 2022May 2025Allow3001NoNo
17918410COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDSOctober 2022November 2025Abandon3701NoNo
17961940LABISIA PUMILA EXTRACT COMPOSITION AND ITS PHARMACEUTICAL FORMULATIONOctober 2022July 2025Allow3301NoNo
17960379METHODS FOR REMOVING CONTAMINANTS FROM PLANT-DERIVED PHARMACEUTICALSOctober 2022October 2025Abandon3601NoNo
17959284MEDICATION SYSTEMOctober 2022July 2024Allow2100NoNo
17937463WATER-BASED CANNABINOID AND OPIOID COMPOSITIONSOctober 2022July 2023Allow900NoNo
17936506Soft GummySeptember 2022July 2025Allow3300NoNo
17956814METHOD TO TREAT VITILIGOSeptember 2022February 2024Abandon1701NoNo
17915233MEANS AND METHODS FOR ENHANCING CANNABINOIDS EFFICACYSeptember 2022October 2025Abandon3601NoNo
17906989PLATELET LYSATE FOAM FOR CELL CULTURE, CELL THERAPY AND TISSULAR REGENERATION AND METHOD FOR OBATINING SAMESeptember 2022October 2025Abandon3701NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MELLER, MICHAEL V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
24
Examiner Affirmed
11
(45.8%)
Examiner Reversed
13
(54.2%)
Reversal Percentile
80.7%
Higher than average

What This Means

With a 54.2% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
140
Allowed After Appeal Filing
52
(37.1%)
Not Allowed After Appeal Filing
88
(62.9%)
Filing Benefit Percentile
61.0%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner MELLER, MICHAEL V - Prosecution Strategy Guide

Executive Summary

Examiner MELLER, MICHAEL V works in Art Unit 1655 and has examined 1,835 patent applications in our dataset. With an allowance rate of 66.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.

Allowance Patterns

Examiner MELLER, MICHAEL V's allowance rate of 66.9% places them in the 28% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MELLER, MICHAEL V receive 1.11 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MELLER, MICHAEL V is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -2.3% benefit to allowance rate for applications examined by MELLER, MICHAEL V. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.5% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 11.6% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 44.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.8% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.3% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.